EBIT Margin (Quarterly)

EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues

BioXcel Therapeutics, Inc. (BTAI) had EBIT Margin of -2866.94% for the most recently reported fiscal quarter, ending 2024-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2024-12-31

Income Statement Financials
Revenue	$0.37M
Net Income	$-10.86M
Cost of Goods Sold	$0.83M
Gross Profit	$-0.47M
Operating Expenses	$10.86M
Operating Income	$-10.49M
Non-Operating Income/Expense	$-0.37M
Pre-Tax Income	$-10.86M
Normalized Pre-Tax Income	$-10.86M
Income after Taxes	$-10.86M
Income from Continuous Operations	$-10.86M
Consolidated Net Income/Loss	$-10.86M
Normalized Income after Taxes	$-10.86M
EBIT	$-10.49M
EBITDA	$-10.42M
Weighted-Average Shares Outstanding (Basic)	2.54M
Weighted-Average Shares Outstanding (Diluted)	2.54M
Earnings per Share (EPS) (Basic)	$-1.11
Earnings per Share (EPS) (Diluted)	$-1.11
Balance Sheet Financials
Current Assets	$37.39M
Property, Plant, and Equipment	$0.47M
Long-Term Assets	$0.94M
Total Assets	$38.34M
Current Liabilities	$22.23M
Long-Term Debt	$102.51M
Long-Term Liabilities	$109.21M
Total Liabilities	$131.44M
Common Equity	$-93.10M
Tangible Shareholders Equity	$-93.10M
Shareholders Equity	$-93.10M
Common Shares Outstanding	3.10M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-72.03M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$36.66M
Beginning Cash	$65.22M
End Cash	$29.85M
Increase/Decrease in Cash	$-35.37M
Stock-Based Compensation	$6.16M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.68
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	10.90
Debt to Equity Ratio	-1.10
Gross Margin	-127.05%
Operating Margin	-2866.94%
EBIT Margin	-2866.94%
EBITDA Margin	--
Pre-Tax Profit Margin	-2966.94%
Profit Margin	-2966.94%
Free Cash Flow	$-72.03M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.01
Inventory Turnover	1.22
Receiveable Turnover	2.79
Days Sales in Receivables	32.21
Return on Equity	11.66%
Return on Tangible Equity	11.66%
Return on Assets	-28.32%
Return on Investments	-115.44%
Book Value Per Share	$-30.01
Free Cash Flow per Share	$-28.41
Operating Cash Flow per Share	$-28.41

Data from Zacks Investment Research, Inc.